Precipio announces the launch of its new quantitative BCR-ABL 2.0 panel, with features making it the most innovative panel of its kind on the market. Patients with Chronic Myeloid Leukemia have cells which contain an abnormal gene, BCR-ABL1. This gene creates a hybrid protein that results in uncontrolled cell division and genomic instability.The presence of the BCR-ABL1 oncogene confirms the diagnosis of CML; it is also used for the monitoring of patients to gauge their response to various therapies, and therefore is frequently tested in laboratories.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRPO:
- Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
- Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven
- Precipio’s operational efficiency measures continue to reduce cash burn
- Precipio reports Q2 revenue $3.5M vs. $2.8M last year
- Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023